Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  temozolomide
Find trials that include:  Any drugs shown
Results 1-25 of 74 for your search:
Start Over
Temozolomide with or without Veliparib in Treating Patients with Newly Diagnosed Glioblastoma Multiforme
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A071102, NCI-2014-00616, CALGB-A071102, NCT02152982
Radiation Therapy with or without Temozolomide in Treating Patients with Anaplastic Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: RTOG 0834, NCI-2011-02070, CAN-NCIC-CEC1, CDR0000582632, COGNO-EORTC-26053, EORTC-22054, EORTC-26053, EUDRACT-2006-001533-17, MERCK-EORTC-26053, MRC-BR14, SPRI-EORTC-26053, CEC1, NCT00626990
Radiation Therapy or Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Anaplastic Glioma or Low Grade Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: N0577, NCI-2011-01915, CDR0000640442, EORTC-26081-22086, EudraCT-2008-007295-14, NCCTG-N0577, NCT00887146
Radiation Therapy with or without Temozolomide in Treating Patients with Low-Grade Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: E3F05, NCI-2011-01971, CDR0000654697, ECOG-E3F05, NCT00978458
PV-10 Intralesional Injection vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PV-10-MM-31, NCI-2015-00568, NCT02288897
Calcitriol and Temozolomide in Treating Patients With Stage IV Melanoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 05M1, NCI-2011-00490, NU-0310-093, SPRI-NU-05M1, NCT00301067
AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 021-003, NCI-2010-01643, NCT00394628
Dose-Intensive Chemotherapy in Combination with Chemoprotected Autologous Stem Cells in Treating Patients with Malignant Gliomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2000.00, NCI-2013-00701, 8357, FHCRC-2000.00, FHCRC-IR-6259, NCT00669669
A Phase I/II Study of TPI 287 - Temozolomide Combination in Melanoma
Phase: Phase II, Phase I
Type: Treatment
Age: 15 and over
Trial IDs: 2009-0357, NCI-2011-00558, NCT01067066
Temozolomide and Hypofractionated Radiation Therapy in Treating Patients With Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BRN0012, NCI-2011-00043, SU-04202010-5726, NCT01120639
Ipilimumab, Combination Chemotherapy, and Biological Therapy in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 2011-0073, NCI-2011-02768, NCT01409174
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: PBTC-033, NCI-2012-00082, 12-C-0213, CDR0000717423, NCT01507324, P12978, NCT01514201
Temozolomide and Pazopanib Hydrochloride in Treating Patients with Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 11I03, NCI-2011-02939, NCT01465659
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PLX108-08, NCI-2013-01176, NCT01790503
Plerixafor after Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed High Grade Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: BRN0023, NCI-2013-02012, 5136, NCT01977677
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: NLG2102, NCI-2014-02063, NCT02052648
BMN-673 and Temozolomide in Treating Younger Patients with Refractory or Recurrent Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 30 years
Trial IDs: ADVL1411, NCI-2014-00804, NCT02116777
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 70 and over
Trial IDs: AVF4535s, NCI-2010-01315, NCT01149850
Radiation Therapy, Bevacizumab, Erlotinib Hydrochloride, or Temozolomide in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 18
Trial IDs: 10-321, NCI-2011-03059, DFCI 10-321, NCT01182350
Temozolomide and Irinotecan Hydrochloride with or without Bevacizumab in Treating Young Patients with Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: ACNS0821, NCI-2011-02605, CDR0000686608, COG-ACNS0821, NCT01217437
Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1076, NCI-2011-00449, 10-008497, NCT01328535
Ondansetron with or without Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients with Gliomas
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: Pro00031206, NCI-2013-00520, NCT01450826
Low-Dose Fractionated Radiation Therapy and Temozolomide in Treating Patients with Recurrent Anaplastic Astrocytoma or Glioblastoma Multiforme
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J11120, NCI-2012-02048, CIR00006742, NA_00065863, NA_00065863_AM00036336, NCT01466686
Combination Chemotherapy with or without Autologous Stem Cell Transplant in Treating Patients with Central Nervous System B-cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 to 70
Trial IDs: CALGB 51101, NCI-2012-00110, CDR0000721927, NCT01511562
Start Over